BackIndo US Bio-Tech Limited Overview

Indo US Bio-Tech Limited EBIT

Indo US Bio-Tech Limited's EBIT is $77M, below the sector sector average of $2.4T.

Get informed when a big investor buys or sells

+ Follow

Quarterly EBIT

-$28.82M
↓ 172.37% YoY

As of Sep 30, 2026

Annual EBIT (TTM)

$77.21M
↓ 58.8% YoY

Trailing 12 months ending Sep 30, 2026

Average EBIT (Comparison Companies)

EBIT History

EBIT Comparison

Annual EBIT Growth Rate (%)

Annual EBIT Growth (Absolute)

Indo US Bio-Tech Limited (INDOUS.BO) FAQ

As of the most recent data (September 2026), INDOUS.BO shows a EBIT of $77M. That compares with $190M in the prior-year period — down 58.8% year over year. That is below the sector sector average of $2.4T. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, INDOUS.BO's EBIT is now $77M (was $190M) — a 58.8% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether Indo US Bio-Tech Limited is outperforming or lagging.

The its sector sector average EBIT is about $2.4T. Indo US Bio-Tech Limited is at $77M, which is lower that average. That is roughly 100.0% below the sector mean. Use the comparison chart on this page to see how INDOUS.BO stacks up against individual peers as well.

Tracking INDOUS.BO's ebit over time shows whether Indo US Bio-Tech Limited is scaling, shrinking, or reshaping that part of the business. The current reading is $77M That compares with $190M in the prior-year period — down 58.8% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this ebit page, Stockcircle has Indo US Bio-Tech Limited's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect EBIT (currently $77M) with ownership activity and broader fundamentals.

Questions & Answers